Worldwide, more than 55 million people are affected by Alzheimer’s Disease (AD) or other dementias. Currently, no effective therapies are available to significantly counteract the development of these pathologies, especially due to the complexity in their cellular and molecular aetiology. The first drugs employed for AD cure were approved at the beginning of the twenty-first century and they are only able to slow down the progression of the disease, without modifying its pathology. Nonetheless, newly approved disease-modifying drugs, i.e. monoclonal antibodies against amyloid β (Aβ) one of the main pathological hallmarks of AD, have opened a window onto the feasibility of effective therapies for AD. Advanced therapy medicinal products are at the forefront of new and innovative AD treatments. Among them gene, RNA and cell therapies are significantly evolving, since their purpose is the tailored targeting of altered molecular mechanisms, therefore providing potentially breakthrough therapeutic strategies.
This Research Topic aims to encourage scientists to focus on the most promising and innovative studies for gene and cell therapy for AD and related disorders.
The submission of original research articles and reviews focused on but not restricted to, the following areas are welcome.
• New insights into AD pathophysiology with a focus on targets for disease-modifying drug development
• Novel gene-, RNA-, or cell-based therapies for AD
• Off-label or repurposed treatment strategies for AD with existing biopharmaceuticals as well as gene and cell therapy
• Delivery strategies for novel advanced therapy medicinal products in AD
• Clinical trials involving gene, RNA, and/or cell therapies in patients
• Obstacles to equitable access for advanced AD therapies
Keywords:
RNA, Bench-to-bedside research, DMTs (disease-modifying therapy), Gene Therapy, Cell Therapy
Important Note:
All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.
Worldwide, more than 55 million people are affected by Alzheimer’s Disease (AD) or other dementias. Currently, no effective therapies are available to significantly counteract the development of these pathologies, especially due to the complexity in their cellular and molecular aetiology. The first drugs employed for AD cure were approved at the beginning of the twenty-first century and they are only able to slow down the progression of the disease, without modifying its pathology. Nonetheless, newly approved disease-modifying drugs, i.e. monoclonal antibodies against amyloid β (Aβ) one of the main pathological hallmarks of AD, have opened a window onto the feasibility of effective therapies for AD. Advanced therapy medicinal products are at the forefront of new and innovative AD treatments. Among them gene, RNA and cell therapies are significantly evolving, since their purpose is the tailored targeting of altered molecular mechanisms, therefore providing potentially breakthrough therapeutic strategies.
This Research Topic aims to encourage scientists to focus on the most promising and innovative studies for gene and cell therapy for AD and related disorders.
The submission of original research articles and reviews focused on but not restricted to, the following areas are welcome.
• New insights into AD pathophysiology with a focus on targets for disease-modifying drug development
• Novel gene-, RNA-, or cell-based therapies for AD
• Off-label or repurposed treatment strategies for AD with existing biopharmaceuticals as well as gene and cell therapy
• Delivery strategies for novel advanced therapy medicinal products in AD
• Clinical trials involving gene, RNA, and/or cell therapies in patients
• Obstacles to equitable access for advanced AD therapies
Keywords:
RNA, Bench-to-bedside research, DMTs (disease-modifying therapy), Gene Therapy, Cell Therapy
Important Note:
All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.